3,908 reports of this reaction
4.0% of all IPRATROPIUM BROMIDE reports
#2 most reported adverse reaction
ASTHMA is the #2 most commonly reported adverse reaction for IPRATROPIUM BROMIDE, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 3,908 FDA adverse event reports linking IPRATROPIUM BROMIDE to ASTHMA. This represents approximately 4.0% of all 98,863 adverse event reports for this drug.
Patients taking IPRATROPIUM BROMIDE who experience asthma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHMA is moderately reported among IPRATROPIUM BROMIDE users, representing a notable but not dominant share of adverse events.
In addition to asthma, the following adverse reactions have been reported for IPRATROPIUM BROMIDE:
The following drugs have also been linked to asthma in FDA adverse event reports:
ASTHMA has been reported as an adverse event in 3,908 FDA reports for IPRATROPIUM BROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHMA accounts for approximately 4.0% of all adverse event reports for IPRATROPIUM BROMIDE, making it one of the most commonly reported side effect.
If you experience asthma while taking IPRATROPIUM BROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.